{
  "id": 219733,
  "title": "Vedanta gets $60M to finish Phase 3 for C. diff microbiome therapy",
  "url": "https://urgent.news/2026/08/06/vedanta-gets-60m-to-finish-phase-3-for-c-diff-microbiome-therapy",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-06T11:00:43.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/vedanta-gets-60m-to-finish-phase-3-for-c-diff-microbiome-therapy/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Investors are pumping more money into one of the microbiome field's longest-standing biotechs to push it toward a Phase 3 readout in C. difficile next year. Cambridge, MA-based Vedanta Biosciences said Thursday its two main ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}